A drug being developed by Boehringer Ingelheim for COVID-19 and reinvented as a potential therapy for kidney disease – and has now hit the mark in a phase 2 trial. TRPC6 inhibitor apecotrep (BI 764198 ...

Boehringer Ingelheim has reported encouraging Phase II trial results for apecotrep (BI 764198), a potential first-in-class oral TRPC6 inhibitor being developed for primary focal segmental ...

Vertex is running a phase 2 trial of inaxaplin in APOL1-mediated kidney diseases, including some forms of FSGS. The phase 3 ...

Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, ...

Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with prima ...

Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with primary focal segmental ...

By placing the cells on surfaces patterned with fractal shapes that mimic natural structures in the kidney, the team ...

Hot chocolate is a winter staple that is rich in sugar and calories. To make a healthier hot chocolate, use unsweetened cocoa powder, stevia, and skim milk.

SonoThera (TM), a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation of genetic medicines, today announced it will officially launch a $125M ...

Chronic kidney disease (CKD) affects more than 700 million people worldwide and is caused by genetic and environmental factors, as well as existing medical conditions. Known genetic risk factors for ...

Chronic kidney disease (CKD) affects more than 10% of the global population and is expected to become the fifth leading cause of death worldwide within the next two decades. Perhaps surprisingly, ...